Established in 1996, this state-of-the-art facility has grown and developed to meet the changing needs of our clients and their regulators, including regular audits to verify our compliance with GMP regulations. This has been integral to our continued success.
Our Centre of Excellence has grown to support the release of biologics on a global scale
- 1996Many of our senior managers work at Q-One Biotech, which started to develop GMP biosafety testing technologies for vaccines, gene therapies and bio-therapeutics.
- 2007Vitrology is set up to create a new contract research organization (CRO) in Glasgow.
- 2012The Vitrology business is acquired by SGS in 2012, to become part of the world’s largest testing, inspection and certification company.
- 2019-22The SGS Centre of Excellence for Biosafety is launched and its Glasgow Centre of Excellence is prepared and equipped for new viral threats or pandemics with our rapid testing platforms. In Glasgow, SGS supports the batch release of over 4 billion doses of the Astra Zeneca COVID-19 vaccine.
- 2022Our capacity is increased to 3,150m² allowing us to provide additional services and resources, including molecular biology, virology, TEM, bioanalysis, sequencing and genetic stability.
- 2024 onwardsMore than GBP 30 million has been invested in the Centre of Excellence since 2007. Further investment is confirmed to expand and double our facilities to 7,000m².